Document is current
Any future updates will be listed below
-
Authors
Steihaug, O. M. https://orcid.org/0000-0002-1849-3910
Sjøset, T. E.
Stordal, A. S.
Sleire, A. D.
Ødegaard-Olsen, O. https://orcid.org/0009-0008-0197-2019
Tunset, A. https://orcid.org/0009-0004-3009-7971
Jammer, I. https://orcid.org/0000-0001-6759-3929
-
Funding
Funding for this research was provided by:
Norwegian Innovation (Grant number 2023/378171)
Norwegian Innovation (Grant number 2023/378171)
Norwegian Innovation (Grant number 2023/378171)
Norwegian Innovation (Grant number 2023/378171)
Norwegian Innovation (Grant number 2023/378171)
Norwegian Innovation (Grant number 2023/378171)
Norwegian Innovation (Grant number 2023/378171)
- License Information
-
More Information
Article History
Received: 13 August 2025
Accepted: 1 February 2026
First Online: 7 February 2026
Declarations
:
: IJ, AT and TS serve as members of Eupnea AS, the company producing the RespX System. ØØ is CEO and founder of Eupnea AS, and IJ, AT, TS and ØØ holds ownership interest in the company.
: REK vest, Bergen, Norway ID: 694285. The study adheres to ISO 14155:2020, MDR 2017/745, and follows the Declaration of Helsinki. Ethical approval was obtained before the study initiation from the Regional committees for medical and health research ethics west (REK: 694285), and informed consent was secured from all participating patients included in the study.
